Profitability Ratios
| Ratio |
Value |
| GP Margin |
57.9% |
| EBIT Margin |
-425.7% |
| EBITDA Margin |
-416.4% |
| Operating Margin |
-425.7% |
| Pretax Margin |
-434.2% |
| Cont. Ops Margin |
-434.2% |
| Net Margin |
-403.8% |
| Bottom Line Margin |
-403.8% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
1.46 |
| Quick Ratio |
1.43 |
| Solvency Ratio |
-0.843 |
| Cash Ratio |
0.63 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.00 |
| Forward PEG |
0.00 |
| Price/Book |
2.80 |
| Price/Sales |
4.05 |
| Price/FCF |
-1.23 |
| Price/Op Cash Flow |
-1.23 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.1561 |
| Debt/Equity |
0.6611 |
| Debt/Capital |
0.3980 |
| Long-Term Debt/Capital |
0.3778 |
| Financial Leverage |
4.23 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.68 |
| Operating Cash Flow Ratio |
-0.976 |
| Operating Cash Flow/Sales |
-328.4% |
| Free Cash Flow/Operating Cash Flow |
100.0% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-19.51 |
| Interest Coverage |
-19.9460 |
| Short-Term Operating Cash Flow Coverage |
0.00 |
| Operating Cash Flow Coverage |
-3.43 |
| Capital Expenditure Coverage |
0.00 |
| Dividend + Capital Expenditure Coverage |
0.00 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.35 |
| EPS |
-1.415 |
| Debt/Share |
0.4099 |
| Cash/Share |
1.43 |
| Book Value/Share |
0.51 |
| Tangible BV/Share |
0.12 |
| Equity/Share |
0.51 |
| Operating Cash Flow/Share |
-1.151 |
| Capital Expenditure/Share |
0.000 |
| FCF/Share |
-1.151 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.930 |
| Earnings Before Tax/EBIT |
1.020 |
| Price/Fair Value |
2.80 |
| Debt/Market Cap |
0.2168 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-0.70 |
CHRS - Coherus Oncology, Inc.